000			01919 a2200565 4500
005			20250517190639.0
264		0	_c20181217
008			201812s 0 0 eng d
022			_a1873-2968
024	7		_a10.1016/j.bcp.2017.11.022 _2doi
040			_aNLM _beng _cNLM
100	1		_aSu, Yongwei
245	0	0	_aTargeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. _h[electronic resource]
260			_bBiochemical pharmacology _c02 2018
300			_a13-26 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntineoplastic Agents _xpharmacology
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Survival _xdrug effects
650	0	4	_aChild
650	0	4	_aChild, Preschool
650	0	4	_aDrug Delivery Systems
650	0	4	_aExtracellular Signal-Regulated MAP Kinases _xgenetics
650	0	4	_aFemale
650	0	4	_aGene Expression Regulation _xdrug effects
650	0	4	_aHumans
650	0	4	_aLeukemia, Myeloid, Acute _xdrug therapy
650	0	4	_aMale
650	0	4	_aMetabolic Networks and Pathways _xdrug effects
650	0	4	_aMiddle Aged
650	0	4	_aPhosphatidylinositol 3-Kinases _xgenetics
650	0	4	_aProto-Oncogene Proteins c-bcl-2 _xgenetics
650	0	4	_aTOR Serine-Threonine Kinases _xgenetics
650	0	4	_aUp-Regulation
650	0	4	_aYoung Adult
700	1		_aLi, Xinyu
700	1		_aMa, Jun
700	1		_aZhao, Jianyun
700	1		_aLiu, Shuang
700	1		_aWang, Guan
700	1		_aEdwards, Holly
700	1		_aTaub, Jeffrey W
700	1		_aLin, Hai
700	1		_aGe, Yubin
773	0		_tBiochemical pharmacology _gvol. 148 _gp. 13-26
856	4	0	_uhttps://doi.org/10.1016/j.bcp.2017.11.022 _zAvailable from publisher's website
999			_c27857460 _d27857460